[1]
|
Adolfsson, R., Gottfries, C. G., Oreland, L., Wiberg, A., & Winblad, B. (1980). Increased Activity of Brain and Platelet Monoamine Oxidase in Dementia of Alzheimer Type. Life Sciences, 27, 1029-1034. https://doi.org/10.1016/0024-3205(80)90025-9
|
[2]
|
Ahlskog, J. E., Uitti, R.J., Low, P. A., Tyce, G. M., O’Brien, J. F., & Nickander, K. K. (1996). Levodopa and Deprenyl Treatment Effects on Peripheral Indices of Oxidant Stress in Parkinson’s Disease. Neurology, 46, 796-801. https://doi.org/10.1212/WNL.46.3.796
|
[3]
|
Alexopoulos, G. S., Young, R. C., Lieberman, K. W., & Shamoian, C. A. (1987). Platelet MAO Activity in Geriatric Patients with Depression and Dementia. American Journal of Psychiatry, 144, 1480-1483. https://doi.org/10.1176/ajp.144.11.1480
|
[4]
|
Ama, O. B., Amita, T., & Youdim, M. B. H. (2004). Contrasting Neuroprotective and Neurotoxic Actions of Respective Metabolites of Anti-Parkinson Drugs Rasagiline and Selegiline. Neuroscience Letters, 355, 169-172. https://doi.org/10.1016/j.neulet.2003.10.067
|
[5]
|
American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). American Psychiatric Association.
|
[6]
|
Amies, P. L., Gelder, M. G., & Shaw, P. M. (1983). Social Phobia: A Comparative Clinical Study. British Journal of Psychiatry, 142, 174-179. https://doi.org/10.1192/bjp.142.2.174
|
[7]
|
Anderson, M. C., Hasan, F., McCrodden, J. M., & Tipton, K. F. (1993). Monoamine Oxidase Inhibitors and the Cheese Effect. Neurochemical Research, 8, 1145-1149. https://doi.org/10.1007/BF00978365
|
[8]
|
Angst, J, Amrein, R., & Stabl, M. (1995). Moclobemide and Tricyclic Antidepressants in Severe Depression: Meta-Analysis and Prospective Studies. Journal of Clinical Psychopharmacology, 15, 16S-23S. https://doi.org/10.1097/00004714-199508001-00004
|
[9]
|
Apaydin, S., Goldeli, E., Uyar, M., Erhan, E., Yegul, I., & Tuglular, I. (2001). The Antinociceptive Effect of Moclobemide on the Vocalization Threshold to Paw Pressure in a Rat Model of Unilateral Mononeuropathy. Pharmacological Research, 44, 503-507. https://doi.org/10.1006/phrs.2001.0895
|
[10]
|
Atchley, D. W. (1964). Reevaluation of Tranylcypromine Sulfate (Parnate Sulfate). Journal of the American Medical Association, 189, 763-764. https://doi.org/10.1001/jama.1964.03070100057011
|
[11]
|
Avramovich-Tirosh, Y., Amit, T., Bar-Am, O., Zheng, H., Fridkin, M., & Youdim, M. B. (2007). Therapeutic Targets and Potential of the Novel Brain-Permeable Multifunctional Iron Chelator-Monoamine Oxidase Inhibitor Drug, M-30, for the Treatment of Alzheimer’s Disease. Journal of Neurochemistry, 100, 490-502. https://doi.org/10.1111/j.1471-4159.2006.04258.x
|
[12]
|
Baker, G. B., Urichuk, L. J., McKenna, K. F., & Kennedy, S. H. (1999). Metabolism of Monoamine Oxidase Inhibitors. Cellular and Mololecular Neurobiology, 19, 411-426. https://doi.org/10.1023/A:1006982732681
|
[13]
|
Baumhackl, U., Bizière, K., Fischbach, R., Geretsegger, C., Hebenstreit, G., Radmayr, E., & Stabl, M. (1989). Efficacy and Tolerability of Moclobemide Compared with Imipramine in Depressive Disorder (DSM-III): An Austrian Double-Blind, Multicentre Study. British Journal Psychiatry, 6, 78-83.
|
[14]
|
Bautista-Aguilera, O. M., Esteban, G., Chioua, M., Nikolic, K., Agbaba, D., Moraleda, I., Iriepa, I., Soriano, E., Samadi, A., Unzeta, M., & Marco-Contelles, J. (2014). Multipotent Cholinesterase/Monoamine Oxidase Inhibitors for the Treatment of Alzheimer’s Disease: Design, Synthesis, Biochemical Evaluation, ADMET, Molecular Modeling, and QSAR Analysis of Novel Donepezil-Pyridyl Hybrids. Drug, Design, Development and Therapy, 8, 1893-1910.
|
[15]
|
Befol—4DOKTOR. RU Drug Information Handbook. http://www.4doktor.ru/default.aspx?drugid=35741.
|
[16]
|
Bellon, A., & Coverdale, J. H. (2009). Delirium, Thrombocytopenia, Insomnia, and Mild Liver Damage Associated with MAOI Withdrawal. European Journal of Clinical Pharmacology, 65, 1269-1270. https://doi.org/10.1007/s00228-009-0711-y
|
[17]
|
Berlin, I., Hunneyball, I. M., Greiling, D., Jones, S. P., Fuder, H., & Stahl, H. D. (2012). A Selective Reversible Monoamine Oxidase B Inhibitor in Smoking Cessation: Effects on Its Own and in Association with Transdermal Nicotine patch. Psychopharmacology (Berlin), 223, 89-98. https://doi.org/10.1007/s00213-012-2692-2
|
[18]
|
Berlin, I., Said, S., Spreux-Varoquaux, O., Launay, J. M., Olivares, R., Millet, V., Lecrubier, Y., & Puech, A. J. (1995). A Reversible Monoamine Oxidase A Inhibitor (Moclobemide) Facilitates Smoking Cessation and Abstinence in Heavy, Dependent Smokers. Clinical Pharmacology & Therapeutics, 58, 444-452. https://doi.org/10.1016/0009-9236(95)90058-6
|
[19]
|
Berlin, I., Spreux-Varoquaux, O., Said, S., & Launay, J. M. (1997). Effects of Past History of Major Depression on Smoking Characteristics, Monoamine Oxidase-A and -B Activities and Withdrawal Symptoms in Dependent Smokers. Drug and Alcohol Dependence, 45, 31-37. https://doi.org/10.1016/S0376-8716(97)01338-0
|
[20]
|
Bianchi, M., Mantegazza, P., & Panerai, A. E. (1992). Effects of Two Different Reversible Monoamine Oxidase-A Inhibitors on Nociceptive Thresholds in the Rat. European Journal of Pharmacology, 219, 113-116. https://doi.org/10.1016/0014-2999(92)90587-T
|
[21]
|
Biberman, R., Neumann, R., Katzir, I., & Gerber, Y. (2003). A Randomized Controlled Trial of Oral Selegiline plus Nicotine Skin Patch Compared with Placebo plus Nicotine Skin Patch for Smoking Cessation. Addiction, 98, 1403-1407. https://doi.org/10.1046/j.1360-0443.2003.00524.x
|
[22]
|
Bisserbe, J. C., & Lépine, J. P. (1994). Moclobemide in Social Phobia: A Pilot Open Study. Clinical Neuropharmacology, 17, S88-S94. https://doi.org/10.1097/00002826-199417001-00010
|
[23]
|
Black, K. J., Hershey. T., Koller, J. M., Videen, T. O., Mintun, M. A., Price, J. L., & Perlmutter, J. S. (2002). A Possible Substrate for Dopamine-Related Changes in Mood and Behavior: Prefrontal and Limbic Effects of a D3-Preferring Dopamine Agonist. Proceedings of the National Academy of Sciences of the United States of America, 99, 17113-17118. https://doi.org/10.1073/pnas.012260599
|
[24]
|
Blackwell, B., & Marl, E. (1964). Interaction between Cheese and Monoamine Oxidase Inhibitors in Rats and Cats. The Lancet, 1, 530-531. https://doi.org/10.1016/S0140-6736(64)92914-9
|
[25]
|
Blackwell, B., & Marley, E. (1966) Interactions of Cheese and of Its Constituents with Monoamine Oxidase Inhibitors. British Journal of Pharmacology and Chemotherapy, 26, 120-141. https://doi.org/10.1111/j.1476-5381.1966.tb01816.x
|
[26]
|
Blackwell, B. (1963). Tranylcypromine. The Lancet, 282, 414. https://doi.org/10.1016/S0140-6736(63)93105-2
|
[27]
|
Blows, W. T. (2000). Neurotransmitters of the Brain: Serotonin, Noradrenaline (Norepinephrine), and Dopamine. Journal of Neuroscience Nursing, 32, 234-238. https://doi.org/10.1097/01376517-200008000-00008
|
[28]
|
Bolea, I., Juárez-Jiménez, J., de Los Ríos, C., Chioua, M., Pouplana, R., Luque, F. J., Unzeta, M., Marco-Contelles, J., & Samadi, A. (2011). Synthesis, Biological Evaluation, and Molecular Modeling of Donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine Hybrids as New Multipotent Cholinesterase/ Monoamine Oxidase Inhibitors for the Treatment of Alzheimer’s Disease. Journal of Medicinal Chemistry, 54, 8251-8270. https://doi.org/10.1021/jm200853t
|
[29]
|
Bonnet, U. (2003). Moclobemide: Therapeutic Use and Clinical Studies. CNS Drug Reviews, 9, 97-140. https://doi.org/10.1111/j.1527-3458.2003.tb00245.x
|
[30]
|
Bravi, D., Mouradian, M. M., Roberts, J. W., Davis, T. L., Sohn, Y. H., & Chase, T.N. (1994). Wearing-Off Fluctuations in Parkinson’s Disease: Contribution of Postsynaptic Mechanisms. Annals of Neurology, 36, 27-31. https://doi.org/10.1002/ana.410360108
|
[31]
|
Bryant, J. M., Torosdag, S., Schvartz, N., Fletcher, L. Jr., Fertig, H., Schwartz, M. S., & Quan, R. B. (1961). Antihypertensive Properties of Pargyline Hydrochloride. New Non-Hydrazine Monoamine Oxidase Inhibitor Compared with Sulphonamide Diuretics. Journal of the American Medical Association, 178, 406-409.
|
[32]
|
Buchsbaum, M. S., Coursey, R. D., & Murphy, D. L. (1976) The Biochemical High-Risk Paradigm: Behavioral and Familial Correlates of Low Platelet Monoamine Oxidase Activity. Science, 194, 339-341. https://doi.org/10.1126/science.968488
|
[33]
|
Burch, D., Asgharnejad, M., Gerson, W., Fielding, R. M., & Azzaro, A.J. (2014). Lack of Tyramine Pressor Response Effect with Oral CX157: A Specific Reversible MAOI. Clinical Pharmacology in Drug Devopment, 3, 4-12. https://doi.org/10.1002/cpdd.61
|
[34]
|
Castilla del Pino, C. (1955). Síndrome hiperesténico. Alteraciones de la personalidad consecutivas a la terapéutica hidrazídica. Actas Luso-Espanolas De Neurologia Y Psiquiatria, 14, 210-219.
|
[35]
|
Cesarman, T. (1957). Serendipitia y angina de pecho. Informe preliminar sobre hallazgo therapeutico. Archivos del Instituto de Cardiologia de Mexico, 27, 563-580.
|
[36]
|
Checchini, S., Petri, P., Ardito, R., Bareggi, S. R., & Torriti, A. (1978). A Comparative Double-Blind Trial of the New Antidepressant Caroxazone and Amitriptyline. Journal of International Medical Research, 6, 388-394. https://doi.org/10.1177/030006057800600507
|
[37]
|
Chen, D. T., & Ruch, R. (1993). Safety of Moclobemide in Clinical Use. Clinical Neuropharmacology, 16, S63-S68.
|
[38]
|
Chessin, M., Dubnick, B., Kramer, E. R., & Scott, C. C. (1957). Modifications of Pharmacology of Reserpine and Isoproniazid. Journal of Pharmacology and Experimental Therapeutics, 119, 453-460.
|
[39]
|
Claman, J. M. (1993). The Potential Effectiveness of Moclobemide, the New Monoamine Oxidase Inhibitor, in the Prophylaxis of Migraine. Headache, 33, 339. https://doi.org/10.1111/j.1526-4610.1993.hed3306339.x
|
[40]
|
Coquoz, D., Porchet, H. C., & Dayer P. (1993). Central Analgesic Effects of Desipramine, Fluvoxamine, and Moclobemide after Single Oral Dosing: A Study in Healthy Volunteers. Clinical Pharmacology & Thereutics, 54, 339-344. https://doi.org/10.1038/clpt.1993.156
|
[41]
|
Cuajungco, M. P., Fagét, K. Y., Huang, X., Tanzi, R. E., & Bush, A. I. (2000). Metal Chelation as a Potential Therapy for Alzheimer’s Disease. Annals of the New York Academy of Sciences, 920, 292-304. https://doi.org/10.1111/j.1749-6632.2000.tb06938.x
|
[42]
|
Curet, O., Damoiseau, G., Aubin, N., Sontag, N., Rovei, V., & Jarreau, F.-X. (1996). Befloxatone, a New Reversible and Selective Monoamine Oxidase-A Inhibitor. I. Biochemical Profile. Journal of Pharmacology and Experimental Therapeutics, 277, 253-264.
|
[43]
|
Curtin, F., Berney, P., & Kaufmann, C. (2002). Moclobemide Discontinuation Syndrome Predominantly Presenting with Influenza-Like Symptoms. Journal of Psychopharmacology, 16, 271-272. https://doi.org/10.1177/026988110201600314
|
[44]
|
Da Prada, M., Kettler, R., Keller, H. H., Burkard, W. P., Muggli-Maniglio, D., & Haefely, W.E. (1989). Neurochemical Profile of Moclobemide, a Short-Acting and Reversible Inhibitor of Monoamine Oxidase Type A. Journal of Pharmacology and Experimental Therapeutics, 248, 400-414.
|
[45]
|
Dahlof, C. G. H. (2001). Sumatriptan: Pharmacological Basis and Clinical Results. Current Medical Research Opinion, 17, s35-s45. https://doi.org/10.1185/0300799039117010
|
[46]
|
Dalsgaard-Neilson, A. T. (1962). Behandling of Migraine-Patienter med Niamid. Ugeskrift for Læger, 124, 10-11.
|
[47]
|
Danish University Antidepressant Group (1991). Moclobemide: A Reversible MAO-AInhibitor Showing Weaker Antidepressant Effect Than Clomipramine in a Controlled Multicenter Study. Journal of Affective Disorders, 28, 105-116.
|
[48]
|
Dashtipour, K., Chen, J. J., Kani, C., Bahjri, K., & Ghamsary, M. (2015). Clinical Outcomes in Patients with Parkinson’s Disease Treated with a Monoamine Oxidase Type-B inhibitor: A Cross-Sectional, Cohort Study. Pharmacotherapy, 35, 681-686. https://doi.org/10.1002/phar.1611
|
[49]
|
Deeks, E. D. (2015). Safinamide: First Global Approval. Drugs, 75, 705-711. https://doi.org/10.1007/s40265-015-0389-7
|
[50]
|
Delumeau, J. C., Bentué-Ferrer, D., Gandon, J. M., Amrein, R., Belliard, S., & Allain, H. (1994). Monoamine Oxidase Inhibitors, Cognitive Functions and Neurodegenerative Diseases. Journal of Neurotransmission Supplement, 41, 259-266.
|
[51]
|
Dilsaver, S. C. (1988). Monoamine Oxidase Inhibitor Withdrawal Phenomena: Symptoms and Pathophysiology. Acta Psychiatrica Scandinavica, 78, 1-7. https://doi.org/10.1111/j.1600-0447.1988.tb06293.x
|
[52]
|
Dorrell, W. (1963). Tranylcypromine and Intracranial Bleeding. The Lancet, 282, 414. https://doi.org/10.1016/S0140-6736(63)93106-4
|
[53]
|
Dvir, Y., & Smallwood, P. (2008). Serotonin Syndrome: A Complex but Easily Avoidable Condition. General Hospital Psychiatry, 30, 284-287. https://doi.org/10.1016/j.genhosppsych.2007.09.007
|
[54]
|
Emilien, G. (1999). Befloxatone (Synthelabo). IDrugs, 2, 247-253.
|
[55]
|
Esuprone. AdisInsights. http://adisinsight.springer.com/drugs/800005281
|
[56]
|
Evotec, Press Release, 30 June 2015. https://www.evotec.com/uploads/cms_article/2739/PR_2015-06 -30_Roche_e.pdf
|
[57]
|
Feighner, J. P., Herbstein, J., & Damlouji, N. (1985). Combined MAOI, TCA and Direct Stimulant Therapy of Treatment-Resistant Depression. Journal of Clinical Psychiatry, 46, 206-209.
|
[58]
|
Fernandez, H. H., & Chen, J. J. (2007) Monoamine Oxidase-B Inhibition in the Treatment of Parkinson’s Disease. Pharmacotherapy, 27, 174S-185S. https://doi.org/10.1592/phco.27.12part2.174S
|
[59]
|
Fiedorowicz, J. G., & Swartz, K. L. (2004). The Role of Monoamine Oxidase Inhibitors in Current Psychiatric Practice. Journal of Psychiatric Practice, 10, 239-248. https://doi.org/10.1097/00131746-200407000-00005
|
[60]
|
Filic, V., Vladic, A., Stefulj, J., Cicin-Sain, L., Balija, M., Sucic, Z., & Jernej, B. (2005). Monoamine Oxidases A and B Gene Polymorphisms in Migraine Patients. Journal of the Neurological Sciences, 228, 149-153. https://doi.org/10.1016/j.jns.2004.11.045
|
[61]
|
Finberg, J. P., Lamensdorf, I, Commissiong, J. W., & Youdim, M. B. (1996). Pharmacology and Neuroprotective Properties of Rasagiline. Journal of Neural Transmission, 48, 95-101.
|
[62]
|
Folks, D. G. (1983). Monoamine Oxidase Inhibitors: Reappraisal of Dietary Considerations. Journal of Clinical Psychopharmacology, 3, 249-252. https://doi.org/10.1097/00004714-198308000-00011
|
[63]
|
Fowler, J. S., Logan, J., Azzaro, A. J., Fielding, R. M., Wei, Z. W., Poshusta, A. K., Burch, D., Brand, B., Free, J., Asgharnejad, M., Wang, G. J., Telang, F., Hubbard, B., Jayne, M., King, P., Carter, P., Carter, S., Xu, Y., Shea, C., Muench, L., Alexoff, D., Shumay, E., Schueller, M., Warner, D., & Apelskog-Torres, K. (2010). Reversible Inhibitors of Monoamine Oxidase-A (RIMAs): Robust, Reversible Inhibition of Human Brain MAO-A by CX157. Neuropsychopharmacology, 35, 623-631. https://doi.org/10.1038/npp.2009.167
|
[64]
|
Fowler, J. S., Logan, J., Wang, J., & Volkow, N. D. (2003). Monoamine Oxidase and Cigarette Smoking. Neurotoxicology, 24, 75-82. https://doi.org/10.1016/S0161-813X(02)00109-2
|
[65]
|
Fowler, J. S., Volkow, N. D., Wang, G. J., Pappas, N., Logan, J., MacGregor, R., Alexoff, D., Shea, C., Schlyer, D., Wolf, A. P., Warner, D., Zezulkova, I., & Cilento, R. (1996). Inhibition of Monoamine Oxidase B in the Brains of Smokers. Nature, 379, 733-736. https://doi.org/10.1038/379733a0
|
[66]
|
Fuller, R. W., & Hemrick, S. K. (1978). Enhanced Selectivity of Pargyline as an Inhibitor of Type B Monoamine Oxidase in Harmaline-Treated Rats. Life Sciences, 22, 1083-1086. https://doi.org/10.1016/0024-3205(78)90278-3
|
[67]
|
Fung, M., Thornton, A., Mybeck, K., Wu, J. H., Hornbuckle, K., & Muniz, E. (2001). Evaluation of the Characteristics of Safety Withdrawal of Prescription Drugs from Worldwide Pharmaceutical Markets—1960 to 1999. Therapeutic Innovation & Regulatory Science, 35, 293-317. https://doi.org/10.1177/009286150103500134
|
[68]
|
Furst, W. (1959). Therapeutic Re-Orientation in Some Depressive States: Clinical Evaluation of a New Mono-Amine Oxidase Inhibitor (W-1554-A, Phenelzine, Nardil). American Journal of Psychiatry, 116, 429-434. https://doi.org/10.1176/ajp.116.5.429
|
[69]
|
Gabelic, I., & Kuhn, B. (1990). Moclobemide (Ro 11-1163) versus Tranylcypromine in the Treatment of Endogenous Depression. Acta Psychiatrica Scandinavica, 360, 63. https://doi.org/10.1111/j.1600-0447.1990.tb05334.x
|
[70]
|
Gachoud, J.-P., Dick, P., & Kohler, M. (1994). Comparison of the Efficacy and Tolerability of Moclobemide and Maprotiline in Depressed Patients Treated by General Practioners. Clinical Neuropharmacology, 17, S29-S37. https://doi.org/10.1097/00002826-199417001-00005
|
[71]
|
George, T. P., Vessicchio, J. C., Termine, A., Jatlow, P. I., Kosten, T. R., & O’Malley, S. S. (2003). A Preliminary Placebo-Controlled Trial of Selegiline Hydrochloride for Smoking Cessation. Biological Psychiatry, 53, 136-143. https://doi.org/10.1016/S0006-3223(02)01454-3
|
[72]
|
Gillman, P. K. (2007). Tricyclic Antidepressant Pharmacology and Therapeutic Drug Interactions Updated. British Journal of Pharmacology, 151, 737-748. https://doi.org/10.1038/sj.bjp.0707253
|
[73]
|
Giroud, C., Horisberger, B., Eap, C., Augsburger, M., Ménétrey, A., Baumann, P., & Mangin, P. (2004) Death Following Acute Poisoning by Moclobemide. Forensic Science International, 140, 101-107. https://doi.org/10.1016/j.forsciint.2003.10.021
|
[74]
|
Gottfries, C. G., Adolfsson, R., Aquilonius, S. M., Carlsson, A., Eckernas, S. A., Nordberg, A., Oreland, L., Svennerholm, L., Wiberg, A., & Winblad, B. (1983). Biochemical Changes in Dementia Disorders of Alzheimer Type (AD/SDAT). Neurobiology of Aging, 4, 261-271. https://doi.org/10.1016/0197-4580(83)90002-7
|
[75]
|
Grady, M. M., & Stahl, S.M. (2012). Practical Guide for Prescribing MAOIs: Debunking Myths and Removing Barriers. CNS Spectrum, 17, 2-10. https://doi.org/10.1017/S109285291200003X
|
[76]
|
Griffith, G. C. (1960). Amine Oxidase Inhibitors; Their Current Place in the Therapy of Cardiovascular Diseases. Circulation, 22, 1156-1165. https://doi.org/10.1161/01.CIR.22.6.1156
|
[77]
|
Guelfi, J. D., Payan, C., Fermanian, J., Pedarriosse, A. M., & Manfredi, R. (1992). Moclobemide vs. Clomipramine in Endogenous Depression. A Double-Blind Randomized Clinical Trial. British Journal of Psychiatry, 160, 519-524. https://doi.org/10.1192/bjp.160.4.519
|
[78]
|
Haefely, W., Burkard, W. P, Cesura, A. M., Kettler, R., Lorez, H. P., Martin, J. R., Richards, J. G., Scherschlicht, R., & De Prada, M. (1992). Biochemistry and Pharmacology of Moclobemide, a Prototype RIMA. Psychopharmacology, 196, S6-S14. https://doi.org/10.1007/BF02246225
|
[79]
|
Hauser, W., Bernardy, K., Uceyler, N., & Sommer, C. (2009). Treatment of Fibromyalgia Syndrome with Antidepressants: A Meta-Analysis. Journal of the American Medical Association, 301, 198-209. https://doi.org/10.1001/jama.2008.944
|
[80]
|
Heinrich, K., & Petrilowitch, N. (1960). [On the Psychopathology and Clinical Aspects of Hydrazines. Comparative Studies with Nialamide, Serine-Isopropylhydrazide and Isocarboxazide]. Medicina Espanol, 2, 162-170.
|
[81]
|
Heinze, G., Rossel, L., Gabelic, I., Galeano-Munoz, J., Stabl, M., & Allen, S. R. (1993). Double-Blind Comparison of Moclobemide and Tranylcypromine in Depression. Pharmacopsychiatry, 26, 240-245. https://doi.org/10.1055/s-2007-1014361
|
[82]
|
Henchcliffe, C., Schumacher, H. C., & Burgut, F. T. (2005). Recent Advances in Parkinson’s Disease Therapy: Use of Monoamine Oxidase Inhibitors. Expert Review in Neurotherapy, 5, 811-821. https://doi.org/10.1586/14737175.5.6.811
|
[83]
|
Hernandez, A. F., Montero, M. N, Pla, A., & Villanueva, E. (1995). Fatal Moclobemide Overdose or Death Caused by Serotonin Syndrome? Journal of Forensic Sciences, 40, 128-130. https://doi.org/10.1520/JFS13776J
|
[84]
|
Herraiz, T., & Chaparro, C. (2005). Human Monoamine Oxidase Enzyme Inhibition by Coffee and Beta-Carbolines Norharman and Harman Isolated from Coffee. Biochemical Biophysical Research Communications, 326, 378-386.
|
[85]
|
Himmelhoch, J. (1995). Monoamine Oxidase Inhibitors. In H. I. Kaplan, & B. J. Sadock (Eds.), Comprehensive Textbook of Psychiatry (Vol. 2, 6th Ed., pp. 2038-2058). Philadelphia: Lippincott, Williams & Wilkins.
|
[86]
|
Huang, L., Lu, C., Sun, Y., Mao, F., Luo, Z., Su, T., Jiang, H., Shan, W., & Li, X. (2012). Multitarget-Directed Benzylideneindanone Derivatives: Anti-β-Amyloid (Aβ) Aggregation, Antioxidant, Metal Chelation, and Monoamine Oxidase B (MAO-B) Inhibition Properties against Alzheimer’s Disease. Journal of Medicinal Chemistry, 55, 8483-8492. https://doi.org/10.1021/jm300978h
|
[87]
|
Hughes, W. (2001). Clinical Pharmacy. In J. Hughes, R. Donnelly & G. James-Chatgilaou (Eds.), A Practical Approach (2nd ed., p. 164). South Yarra: Macmillan Publishers Australia Pty Ltd.
|
[88]
|
Jossan, S. S., Ekblom, J., Aquilonius, S. M., & Oreland, L. (1994). Monoamine Oxidase-B in Motor Cortex and Spinal Cord in Amyotrophic Lateral Sclerosis Studied by Quantitative Autoradiography. Journal of Neural Transmission, 41, 243-248.
|
[89]
|
Jouvent, R., Le Houezec, J., Payan, C., Mikkelsen, H., Fermanian, J., Millet, V., & Dufour, H. (1998). Dimensional Assessment of Onset of Action of Antidepressants: A Comparative Study of Moclobemide vs. Clomipramine in Depressed Patients with Blunted Affect and Psychomotor Retardation. Psychiatric Research, 79, 267-275. https://doi.org/10.1016/S0165-1781(98)00046-8
|
[90]
|
Kan, J. P., Mouget-Goniot, C., Worms, P., & Biziere, K. (1986). Effect of the Antidepressant Minaprine on Both Forms of Monoamine Oxidase in the Rat. Biochemical Pharmacology, 35, 973-978. https://doi.org/10.1016/0006-2952(86)90085-7
|
[91]
|
Katschnik, H., Murray, B., & Buller, R. (1997). The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in Social Phobia. A Double-Blind, Placebo-Controlled Clinical Study. European Archives of Psychiatry and Clinical Neuroscience, 247, 71-80.
|
[92]
|
Kennedy, B. P., Ziegler, M. G., Alford, M., Hansen, L. A., Thal, L. J., & Masliah, E. (2003). Early and Persistent Alterations in Prefrontal Cortex MAO A and B in Alzheimer’s Disease. Journal of Neural Transmission (Vienna), 110, 789-801.
|
[93]
|
Kettler, R., Da Prada, M., & Burkard, W. P. (1990) Comparison of Monoamine Oxidase-A Inhibition by Moclobemide in Vitro and ex Vivo in Rats. Acta Psychiatrica Scandinavica, 82, 101-102. https://doi.org/10.1111/j.1600-0447.1990.tb05348.x
|
[94]
|
Killen, J. D., Fortmann, S. P., Murphy Jr., G. M., Hayward, C., Fongm D., Lowenthal, K., Bryson, S. W., Killen D. T., & Schatzberg, A. F. (2010). Failure to Improve Cigarette Smoking Abstinence with Transdermal Selegiline + Cognitive Behavior Therapy. Addiction, 105, 1660-1668. https://doi.org/10.1111/j.1360-0443.2010.03020.x
|
[95]
|
Kimball, R. W., Friedman, A. P., & Vallejo, E. (1960). Effect of Serotonin in Migraine Patients. Neurology, 10, 107-111. https://doi.org/10.1212/WNL.10.2.107
|
[96]
|
Kline, N. S., & Cooper, T. B. (1980). Monoamine Oxidase Inhibitors as Antidepressants. In F. Hoffmeister, & G. Stille (Eds.), Psychotrophic Agents (pp. 369-397). Weinheim: Springer-Verlag. https://doi.org/10.1007/978-3-642-67538-6_17
|
[97]
|
Kline, N.S. (1970). Monoamine Oxidase Inhibitors: An Unfinished, Picturesque Tale. In F. J. Ayd, & B. Blackwell (Eds.), Discoveries in Biological Psychiatry (pp. 194-214). Philadelphia: Lippincott.
|
[98]
|
Knoll, J., & Magyar, K. (1972). Some Puzzling Effects of Monoamine Oxidase Inhibitors. Advances in Biochemical Psychopharmacology, 5, 393-408.
|
[99]
|
Knudsen-Gerber, D. S. (2011). Selegiline and Rasagiline: Twins or Distant Cousins? Consultant Pharmacist, 26, 48-51. https://doi.org/10.4140/TCP.n.2011.48
|
[100]
|
Kok, L. P., & Tsoi, W. F. (1995). A Controlled Double-Blind Trial of Moclobemide and Imipramine in the Treatment of Depression. Singapore Medical Journal, 36, 38-40.
|
[101]
|
Kong, P., Zhang, B., Lei, P., Kong, X., Zhang, S., Li, D., & Zhang, Y. (2015). Neuroprotection of MAO-B Inhibitor and Dopamine Agonist in Parkinson Disease. International Journal of Clinical and Experimental Medicine, 8, 431-439.
|
[102]
|
Korenchuk, S., Lehr, J. E., Mclean, L., Lee, Y. G., Whitney, S., Vessella, R., Lin, D. L., & Pienta, K. J. (2001). VCaP, a Cell-Based Model System of Human Prostate Cancer. In-Vivo, 15, 163-168.
|
[103]
|
Kragh-Sorensen, P. (1993). Randomized, Double-Blind, Parallel, Multi-Centre Study of Moclobemide vs. Clomipramine in Depressive Patients in General Practice. Eur Neuropsychopharmacology, 3, 359. https://doi.org/10.1016/0924-977X(93)90143-A
|
[104]
|
Krishnan, K. R. R. (2013) Monoamine Oxidase Inhibitors. In A. F. Schatzberg, & C. B. Nemeroff (Eds.), Essentials of Clinical Psychopharmacology (pp. 119-136). Arlington: American Psychiatric Publishing.
|
[105]
|
Lamensdorf, I., Porat, S., Simantov, R., & Finberg, J.P. (1999) Effect of Low-Dose Treatment with Selegiline on Dopamine Transporter (DAT) Expression and Amphetamine-Induced Dopamine Release in Vivo. British Journal of Pharmacology, 126, 997-1002. https://doi.org/10.1038/sj.bjp.0702389
|
[106]
|
Larsen, J. K., & Rafaelsen, O. J. (1980). Long-Term Treatment of Depression with Isocarboxazide. Acta Psychiatrica Scandinavica, 62, 456-463. https://doi.org/10.1111/j.1600-0447.1980.tb00634.x
|
[107]
|
Larsen, J. K., Gjerris, A., Holm, P., Andersen, J., Bille, A., Christensen, E. M., Høyer, E., Jensen, H., Mejlhede, A., Langargergaard, A., Laursen, A. L., Nilakantan, B., Olafsson, K., Severin B., & Rafaelsen, O. J. (1991). Moclobemide in Depression: A Randomized Multicentre Trial against Isocarboxazide and Clomipramine Emphasizing Atypical Depression. Acta Psychiatrica Scandinavica, 84, 564-570. https://doi.org/10.1111/j.1600-0447.1991.tb03196.x
|
[108]
|
Laux, G., Volz, H. P., & Moller, H. J. (1995). Newer and Older Monoamine Oxidase Inhibitors. A Comparative Profile. CNS Drugs, 3, 145-158. https://doi.org/10.2165/00023210-199503020-00006
|
[109]
|
Lecrubier, Y., & Guelfi, J. D. (1990). Efficacy of Reversible Inhibitors of Monoamine Oxidase A in Various Forms of Depression. Acta Psychiatrica Scandinavica, 82, 18-23. https://doi.org/10.1111/j.1600-0447.1990.tb05319.x
|
[110]
|
Lecrubier, Y., Pedarriosse, A.-M., Payan, C., Schmid-Burgk, W., & Stabl, M. (1995). Moclobemide vs. Clomipramine in Nonmelancholic, Nonpsychotic Major Depression. A Study Group. Acta Psychiatrica Scandinavica, 92, 260-265. https://doi.org/10.1111/j.1600-0447.1995.tb09580.x
|
[111]
|
Lee, H. T., Choi, M. R., Doh, M. S., Jung, K. H., & Chai, Y. G. (2013). Effects of the Monoamine Oxidase Inhibitors Pargyline and Tranylcypromine on Cellular Proliferation in Human Prostate Cancer Cells. Oncology Reports, 30, 1587-1592.
|
[112]
|
Lee, H. T., Jung, K. H., Kim, S. K., Choi, M. R., & Chai, Y. G. (2012). Effects of Pargyline on the Cellular Proliferation in Human Breast Cancer Cells. Molecular & Cellular Toxicology, 8, 393-399. https://doi.org/10.1007/s13273-012-0048-y
|
[113]
|
Li, Y., Qiang, X., Luo, L., Li, Y., Xiao, G., Tan, Z., & Deng, Y. (2016). Synthesis and Evaluation of 4-Hydroxyl Aurone Derivatives as Multifunctional Agents for the Treatment of Alzheimer’s Disease. Bioorganic & Medicinal Chemistry, 24, 2342-2351. https://doi.org/10.1016/j.bmc.2016.04.012
|
[114]
|
Liebowitz, M. R., Gorman, J. M., Fyer, A. J., & Klein, D. F. (1985). Social Phobia. Review of a Neglected Anxiety Disorder. Archives of General Psychiatry, 42, 729-736. https://doi.org/10.1001/archpsyc.1985.01790300097013
|
[115]
|
Lingjaerde, O., Jørgensen, J., Støren, R., Thomle, S., Wendt Raeder, L., Ruud, L. E., Schetelig, E., Sveaas, H. K., & Leivestad, O. (1995). A Double-Blind Comparison of Moclobemide and Doxepin in Depressed General Practice Patients. Acta Psychiatrica Scandinavica, 92, 125-131. https://doi.org/10.1111/j.1600-0447.1995.tb09555.x
|
[116]
|
Lonnqvist, J., Sihvo, S., Syvalahti, E., & Kiviruusu, O. (1994). Moclobemide and Fluoxetine in Atypical Depression: A Double-Blind Trial. Journal of Affective Disorders, 32, 169-177. https://doi.org/10.1016/0165-0327(94)90015-9
|
[117]
|
Loomer, H. F., Saunders, J. C., & Kline, N. S. (1957). A Clinical and Pharmacodynamic Evaluation of Iproniazid as a Psychic Energizer. Psychiatric Research Reports of the American Psychiatric Association, 9, 129-141.
|
[118]
|
Lotufo-Neto, F., Trivedi, M., & Thase, M. E. (1999). Meta-Analysis of the Reversible Inhibitors of Monoamine Oxidase Type A Moclobemide and Brofaromine for the Treatment of Depression. Neuropsychopharmacoogy, 20, 226-247. https://doi.org/10.1016/S0893-133X(98)00075-X
|
[119]
|
Lum, C. T., & Stahl, S. M. (2012). Opportunities for Reversible Inhibitors of Monoamine Oxidase-A (RIMAs) in the Treatment of Depression. CNS Spectrums, 17, 107-120. https://doi.org/10.1017/S1092852912000594
|
[120]
|
Magyar, K., & Knoll, J. (1977). Selective inhibition of the “B Form” of Monoamine Oxidase. Polish Journal of Pharmacology and Pharmacy, 29, 233-246.
|
[121]
|
Mallinger, A. G., Frank, E., Thase, M. E., Barwell, M. M., Diazgranados, N., Luckenbaugh, D. A., & Kupfer, D. J. (2009). Revisiting the Effectiveness of Standard Antidepressants in Bipolar Disorder: Are Monoamine Oxidase Inhibitors Superior? Psychopharmacology Bulletin, 42, 64-74.
|
[122]
|
Marks, J. (1965). Interactions Involving Drugs. In J. Marks, & C. M. B. Pare (Eds.), Scientific Basis of Drug Therapy in Psychiatry (pp. 191-201), Oxford, New York: Pergamon Press. https://doi.org/10.1016/B978-0-08-011195-7.50026-5
|
[123]
|
Martini, A., Bonollo, L., Nicolis, F. B., Sega, R., Palermo, A., & Braibanti, E. (1981). Effects of Caroxazone, a Reversible Monoamine Oxidase Inhibitor, on the Pressor Response to Intravenous Tyramine in Man. British Journal Clinical Pharmacology, 11, 605-610. https://doi.org/10.1111/j.1365-2125.1981.tb01177.x
|
[124]
|
Mashkovsky, M. D., & Andrejeva, N. I. (1981). Pharmacological Properties of 2, 3, 3a, 4, 5, 6-hexahydro-8-methyl-1H-pyrazino [3, 2, 1-j, k] Carbazol Hydrochloride (Pirlindole), a New Antidepressant. Arzneimittel Forschung, 31, 75-79.
|
[125]
|
Mayersohn, M., & Guentert, T. W. (1995). Clinical Pharmacokinetics of the Monoamine oxidase-A Inhibitor Moclobemide. Clinical Pharmacokinetics, 29, 292-332. https://doi.org/10.2165/00003088-199529050-00002
|
[126]
|
Meienberg, O., & Amsler, F. (1996). Moclobemide in the Prophylactic Treatment of Migraine. A Retrospective Analysis of 44 Cases. European Neurology, 36, 109-110. https://doi.org/10.1159/000117221
|
[127]
|
Meienberg, O., & Amsler, F. (1997). Preventive Treatment of Migraine and Chronic Tension Headache with Moclobemide. Praxis (Bern 1994), 86, 1107-1112.
|
[128]
|
Merikangas, K. R., & Merikangas, J. R. (1995). Combination Monoamine Oxidase Inhibitor and Beta-Blocker Treatment of Migraine, with Anxiety and Depression. Biological Psychiatry, 38, 603-610. https://doi.org/10.1016/0006-3223(95)00077-1
|
[129]
|
Michelacci, S., & Franchi, G. (1962). Treatment of Vascular Headaches. Minerva Medica, 53, 1521-1523.
|
[130]
|
Micó, J. A., Ardid, D., Berrocoso, E., & Eschalier, A. (2006). Antidepressants and Pain. Trends in Pharmacological Sciences, 27, 348-354. https://doi.org/10.1016/j.tips.2006.05.004
|
[131]
|
Miller, R. B. (1963). Tranylcypromine and Cheese. British Medical Journal, 2, 1593. https://doi.org/10.1136/bmj.2.5372.1593-a
|
[132]
|
Miner, C. M., Conner, K. M., & Davidson, J. R. T. (2000). New Treatments for Social Phobia. In U. Halbreich, & S. A. Montgomery (Eds.), Pharmacotherapy for Mood, Anxiety, and Cognitive Disorders (pp. 389-398). Arlington: American Psychiatric Association Publishing.
|
[133]
|
Montgomery, S. A., Baldwin, D. S., Priest, R. G, Steinert, J., Patel, A., Herrington, R. N., & Livingston, H.M. (1991) Minaprine and Dose Response in Depression. An Investigation of Two Fixed Doses of Minaprine Compared with Imipramine. Pharmacopsychiatry, 5, 168-174. https://doi.org/10.1055/s-2007-1014463
|
[134]
|
Mostert, S., Petzer, A., & Petzer, J. P. (2016). Inhibition of Monoamine Oxidase by Benzoxathiolone Analogues. Bioorganic Medicinal Chemistry Letters, 26, 1200-1204. https://doi.org/10.1016/j.bmcl.2016.01.034
|
[135]
|
Mrazek, D. A., Hornberger, J. C., Altar, C. A., & Degtiar, I. (2014). A Review of the Clinical, Economic, and Societal Burden of Treatment-Resistant Depression: 1996-2013. Psychiatric Services, 65, 977-987. https://doi.org/10.1176/appi.ps.201300059
|
[136]
|
Nair, N. P., Ahmed, S. K., & Kin, N. M. (1993). Biochemistry and Pharmacology of Reversible Inhibitors of MAO-A Agents: Focus on Moclobemide. Journal of Psychiatry and Neurosciences, 18, 214-225.
|
[137]
|
Naoi, M., Maruyama, W., & Inaba-Hasegawa, K. (2012). Type A and B Monoamine Oxidase in Age-Related Neurodegenerative Disorders: Their Distinct Roles in Neuronal Death and Survival. Current Topics in Medicinal Chemistry, 12, 2177-2188. https://doi.org/10.2174/156802612805219950
|
[138]
|
Naoi, M., Maruyama, W., Inaba-Hasegawa, K., & Akao, Y. (2011). Type A Monoamine Oxidase Regulates Life and Death of Neurons in Neurodegeneration and Neuroprotection. International Review of Neurobiology, 100, 85-106. https://doi.org/10.1016/B978-0-12-386467-3.00005-4
|
[139]
|
Natoli, J. L., Manack, A., Dean, B., Butler, Q., Turkel, C. C., Stovner, L. & Lipton, R. B. (2010). Global Prevalence of Chronic Migraine: A Systematic Review. Cephalalgia, 30, 599-609. https://doi.org/10.1111/j.1468-2982.2009.01941.x
|
[140]
|
Norman, T. R., Chamberlain, K. G., & French, M. A. (1987). Platelet Monoamine Oxidase: Low Activity in Cigarette Smokers. Psychiatry Research, 20, 199-205. https://doi.org/10.1016/0165-1781(87)90079-5
|
[141]
|
Norman, T. R., Chamberlain, K. G., French, M. A., & Burrows, G. D. (1982). Platelet Monoamine Oxidase Activity and Cigarette Smoking. Journal of Affective Disorders, 4, 73-77. https://doi.org/10.1016/0165-0327(82)90021-0
|
[142]
|
Noyes Jr., R., Moroz, G., Davidson, J. R., Liebowitz, M. R., Davidson, A., Siegel, J., Bell, J., Cain, J. W., Curlik, S. M., Kent, T. A., Lydiard, R. B., Mallinger, A. G., Pollack, M. H., Rapaport, M., Rasmussen, S.A., Hedges, D., Schweizer, E., & Uhlenhuth, E. H. (1997). Moclobemide in Social Phobia: A Controlled Dose-Response Trial. Journal of Clinical Psychopharmacology, 17, 247-254. https://doi.org/10.1097/00004714-199708000-00002
|
[143]
|
Oreland, L., & Gottfries, C. G. (1986). Brain and Brain Monoamine Oxidase in Aging and in Dementia of Alzheimer’s Type. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 10, 533-540. https://doi.org/10.1016/0278-5846(86)90023-0
|
[144]
|
Oreland, L. (1991). Monoamine Oxidase, Dopamine and Parkinson’s Disease. Acta Neurologica Scandinavica, 136, 60-65. https://doi.org/10.1111/j.1600-0404.1991.tb05021.x
|
[145]
|
Oreland, L., Fowler, C. J., & Schalling, D. (1981). Low Platelet Monoamine Oxidase Activity in Cigarette Smokers. Life Sciences, 29, 2511-2518. https://doi.org/10.1016/0024-3205(81)90706-2
|
[146]
|
Pallanti, S., Quercioli, L., & Hollander, E. (2004). Social Anxiety in Outpatients with Schizophrenia. A Relevant Cause of Disability. American Journal of Psychology, 161, 53-58. https://doi.org/10.1176/appi.ajp.161.1.53
|
[147]
|
Pande, A. C., Birkett, M., Fechner-Bates, S., Haskett, R. F., & Greden, J. F. (1996). Fluoxetine versus Phenelzine in Atypical Depression. Biological Psychiatry, 40, 1017-1020. https://doi.org/10.1016/0006-3223(95)00628-1
|
[148]
|
Parkinson Study Group (1993). Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson’s Disease. New England Journal of Medicine, 328, 176-183. https://doi.org/10.1056/NEJM199301213280305
|
[149]
|
Parkinson Study Group (2004). A Controlled, Randomized, Delayed-Start Study of Rasagiline in Early Parkinson Disease. Archives of Neurology, 61, 561-566. https://doi.org/10.1001/archneur.61.4.561
|
[150]
|
Patat, A., Berlin, I., Durrieu, G., Armand, P., Fitoussi, S., Molinier, P., & Caille, P. (1995). Pressor Effect of Oral Tyramine during Treatment with Befloxatone, a New Reversible Monoamine Oxidase-A Inhibitor, in Healthy Subjects. The Journal of Clinical Pharmacology, 35, 633-643. https://doi.org/10.1002/j.1552-4604.1995.tb05022.x
|
[151]
|
Phillip, M., Kohnen, R., & Benkert, O. (1993). A Comparison Study of Moclobemide and Doxepin in Major Depression with Special Reference to Effects on Sexual Dysfunction. International Clinical Psychopharmacology, 7, 149-153. https://doi.org/10.1097/00004850-199300730-00005
|
[152]
|
Pirildar, S., Sezgin, U., Elbi, H., Uyar, M., & Zileli, B. (2003). A Preliminary Open-Label Study of Moclobemide Treatment of Pain Disorder. Psychopharmacology Bulletin, 37, 127-134.
|
[153]
|
Pray, W. S. (2007). Interactions between Nonprescription Products and Psychotropic Medications. US Pharmacist, 32, 12-15.
|
[154]
|
Rascol, O., Brooks, D. J., Melamed, E., Oertel, W., Poewe, W., Stocchi, F., & Tolosa, E., LARGO Study Group (2005). Rasagiline as an Adjunct to Levodopa in Patients with Parkinson’s Disease and Motor Fluctuations (LARGO, Lasting Effect in Adjunct Therapy with Rasagiline Given Once Daily, Study): A Randomised, Double-Blind, Parallel-Group Trial. The Lancet, 365, 947-954. https://doi.org/10.1016/S0140-6736(05)71083-7
|
[155]
|
Remick, R. A., & Froese, C. (1990). Monoamine Oxidase Inhibitors: Clinical Review. Canadian Family Physician, 36, 1151-1155.
|
[156]
|
Rendenbach-Mueller, B., Schlecker, R., Traut, M., & Weifenbach, H. (1994). Synthesis of Coumarins as Subtype-Selective Inhibitors of Monoamine Oxidase. Bioorganic Medicinal Chemistry Letters, 4, 1195-1198. https://doi.org/10.1016/S0960-894X(01)80328-0
|
[157]
|
Riederer, P., & Laux, G. (2011). MAO-Inhibitors in Parkinson’s Disease. Experimental Neurobiology, 20, 1-17. https://doi.org/10.5607/en.2011.20.1.1
|
[158]
|
Rimon, R., Jaaskelainen, J., Kaartinen, P., Kalli, A., Kilponen, E., Koskinen, T., Nikkila, H., Pirttipera, V., & Seppala, J. (1993). Moclobemide vs. Imipramine in Depressed Out-Patients: A Double Blind Multi-Centre Study. International Clinical Psychopharmacology, 7, 141-147. https://doi.org/10.1097/00004850-199300730-00004
|
[159]
|
Robakis, D., & Fahn, S. (2015). Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson’s Disease. CNS Drugs, 29, 433-441. https://doi.org/10.1007/s40263-015-0249-8
|
[160]
|
Robbins, L., & Lang, S. S. (2000). Headache Help: A Complete Guide to Understanding Headaches and the Medicines to Relieve Them (p. 162). Boston: Hughton Mifflin Harcourt.
|
[161]
|
Rossel, L., & Moll, E. (1990). Moclobemide versus Tranylcypromine in the Treatment of Depression. Acta Psychiatrica Scandinavica, 360, 61-62. https://doi.org/10.1111/j.1600-0447.1990.tb05333.x
|
[162]
|
Ruggieri, S., Fabbrini, G., Bramante, L., De Pandis, F., Stocchi, F., Barbanti, P., Vacca, L., & Manfredi, M. (1996). An Open Study with Reversible MAO-A Inhibitors in Complicated Parkinson’s Disease. Advances in Neurology, 69, 595-598.
|
[163]
|
Ruggieri, S., Stocchi, F., Bramante, L., De Pandis, M. F., Barbato, L., Bolner, A., Berardelli, A., & Manfredi, M. (1994). MAO-A Inhibitor Moclobemide Has a Sympatomatic Effect in Parkinson’s Disease. Movement Disorders, 9, 72.
|
[164]
|
Sadock, B. J., Sadock, V. A., & Sussman, N. (2014). Kaplan & Sadock’s Pocket Handbook of Psychiatric Drug Treatment (5th ed.). Philadelphia: Lippincott, Williams & Wilkins.
|
[165]
|
Sandler, M., Glover, V., Ashford, A., & Esmail A. (1980). The Inhibition of Tyramine Oxidation and the Tyramine Hypertensive Response (“Cheese Effect”) May Be Independent Phenomena. Journal of Neural Transmission, 48, 241-247. https://doi.org/10.1007/BF01250659
|
[166]
|
Sandyk, R., & Iacono, R. P. (1987). Phenelzine in Migraine Headaches. International Journal Neuroscience, 35, 243. https://doi.org/10.3109/00207458708987135
|
[167]
|
Saunders, J. C., Roukema, R. W., Kline, N. S., & Bailey S. D. (1959). Clinical Results with Phenelzine. American Journal Psychiatry, 116, 71-72. https://doi.org/10.1176/ajp.116.1.71
|
[168]
|
Saura, J., Luque, J. M., Cesura, A. M., Da Prada, M., Chan-Palay, V., Huber, G., Loffler, J., & Richards, J. G. (1994). Increased Monoamine Oxidase B Activity in Plaque-Associated Astrocytes of Alzheimer Brains Revealed by Quantitative Enzyme Radioautography. Neuroscience, 62, 15-30. https://doi.org/10.1016/0306-4522(94)90311-5
|
[169]
|
Saxena, P. R., & Ferrari, M. D. (1992). From Serotonin Receptor Classification to the Antimigraine Drug Sumatriptan. Cephalalgia, 12, 187-196. https://doi.org/10.1046/j.1468-2982.1992.1204187.x
|
[170]
|
Shapira, A, Bate, G., & Kirkpatrick, P. (2005). Rasagiline. Nature Reviews of Drug Discovery, 4, 625-626. https://doi.org/10.1038/nrd1803
|
[171]
|
Shapira, A. H. (2011). Monoamine Oxidase B Inhibitors for the Treatment of Parkinson’s Disease: A Review of Symptomatic and Potential Disease-Modifying Effects. CNS Drugs, 25, 1061-1071. https://doi.org/10.2165/11596310-000000000-00000
|
[172]
|
Schlecker, R., Schmidt, P., Thieme, P. C., Lenke, D., Teschendorf, H. J., Traut, M., Mueller, C., Hofmann, H. P., & Kreiskott, H. (1984). Sulfonic Acid Esters of Hydroxycoumarins. German Offenlegungsschrift, DE3243158A1.
|
[173]
|
Schoerlin, M. P., & Da Prada, M. (1990). Species-Specific Biotransformation of Moclobemide: A Comparative Study in Rats and Humans. Acta Psychiatrica Scandinavica, 82, 108-110. https://doi.org/10.1111/j.1600-0447.1990.tb05351.x
|
[174]
|
Shaikh, W., & Fuls, K. (2009). Tranylcypromine Dependence and Withdrawal. Australian and New Zealand Journal of Psychiatry, 6, 580-581.
|
[175]
|
Sherif, F., Gottfries, C. G., Alafuzoff, I., & Oreland, L. (1992). Brain Gamma-Aminobutyrate Aminotransferase (GABA-T) and Monoamine Oxidase (MAO) in Patients with Alzheimer’s Disease. Journal of Neural Transmission-Parkinson’s Disease and Dementia Section, 4, 227-240. https://doi.org/10.1007/BF02260906
|
[176]
|
Shorter, E. (2008). Before Prozac: The Troubled History of Mood Disorders in Psychiatry. Oxford: Oxford University Press.
|
[177]
|
Shoulson, I. (1998). DATATOP: A Decade of Neuroprotective Inquiry. Parkinson Study Group. Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism. Annals of Neurology, 44, S160-S166. https://doi.org/10.1002/ana.410440724
|
[178]
|
Shulman, K. I., Herrmann, N., & Walker, S. E. (2013). Current Place of Monoamine Oxidase Inhibitors in the Treatment of Depression. CNS Drugs, 27, 789-797. https://doi.org/10.1007/s40263-013-0097-3
|
[179]
|
Shvedov, V. I., Altukhova, L. B., Andreeva, N. I., Mashkovskii, M., & Grinev, A. N. (1972). [Derivatives of pyrazino- and piperazino[1, 2-a] indole]. Khimiko Farmatsevticheskii Zhurnal, 6, 14-17. https://doi.org/10.1007/bf00771296
|
[180]
|
Silverstone, T., Abou-Saleh, M. T., Pathak, R., Lock, T., Bennie, E., Mohammed, Y., Chakravarti, S. K., Jauhar, P., Katona, C., Shamash, K., Khan, M. C., Livingston, M., Cahill, C., Sharma, V. K., Singh, V., Cookson, J., Sireling, L. I., Morgan, J., & Suri, A. K. (1994). A Multicentre Comparative Trial of Moclobemide, Imipramine and Placebo in Major Depressive Disorder. International Clinical Psychopharmacology, 9, 109-113. https://doi.org/10.1097/00004850-199400920-00007
|
[181]
|
Simpson, G. M., Shih, J. C., Chen, K., Flowers, C., Kumazawa, T., & Spring, B. (1999). Schizophrenia, Monoamine Oxidase Activity, and Cigarette Smoking. Neuropsychopharmacology, 20, 392-394. https://doi.org/10.1016/S0893-133X(98)00119-5
|
[182]
|
Singh, T., & Williams, K. (2006). Atypical Depression. Psychiatry, 3, 33-39.
|
[183]
|
Siever, L. J., Uhde, T. W., & Murphy, P. L. (1982). Possible Sub-Sensitization of Alpha 2-Adrenergic Receptors by Chronic Monoamine Oxidase Treatment in Psychiatric Patients. Psychiatric Research, 6, 293-302.
|
[184]
|
Son, S. Y., Ma, J., Kondou, Y., Yoshimura, M., Yamashita, E., & Tsukihara, T. (2008). Structure of Human Monoamine Oxidase A at 2.2-A Resolution: The Control of Opening the Entry for Substrates/Inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 105, 5739-5744. https://doi.org/10.1073/pnas.0710626105
|
[185]
|
Sparks, D. L., Woeltz, V. M., & Markesbery, W. R. (1991). Alterations in Brain Monoamine Oxidase Activity in Aging, Alzheimer’s Disease, and Pick’s Disease. Archives of Neurology, 48, 718-721. https://doi.org/10.1001/archneur.1991.00530190064017
|
[186]
|
Stabl, M., Biziére, K., Schmid-Burgk, W., & Amrein, R. (1989). Review of Comparative Clinical Trials. Moclobemide vs Tricyclic Antidepressants and vs Placebo in Depressive States. Journal of Neural Transmission, 28, 77-89.
|
[187]
|
Stein, D. J., Cameron, A., Amrein, R., & Montgomery, S. A. (1996). Moclobemide Social Phobia Clinical Study Group. Moclobemide Is Effective and Well Tolerated in the Long-Term Pharmacotherapy of Social Anxiety Disorder with or without Comorbid Anxiety Disorder. International Clinical Psychopharmacology, 11, 83-88.
|
[188]
|
Steinmeyer, E. M., Vorbach, E. U., & Arnoldt, K. H. (1993). Efficacy and Safety of Moclobemide Compared with Maprotiline in Treatment of Major Depressive Disorder —A Double-Blind Multicenter Study with Parallel Groups. Pharmacopsychiatry, 26, 246-253. https://doi.org/10.1055/s-2007-1014362
|
[189]
|
Sternic, N., Kacar, A., Filipovic, S., Svetel, M., & Kostic, V.S. (1998). The Therapeutic Effect of Moclobemide, a Reversible Selective Monoamine Oxidase A Inhibitor, in Parkinson’s Disease. Clinical Neuropharmacology, 21, 93-96.
|
[190]
|
Strolin Benedetti, M., &, Dostert, P. (1987) Overview of the Present State of MAO Inhibitors. Journal of Neural Transmission, 23, 103-119. https://doi.org/10.1007/978-3-7091-8901-6_7
|
[191]
|
Sun-Edelstein, C., Tepper, S. J., & Shapiro, R. E. (2008). Drug-Induced Serotonin Syndrome: A Review. Expert Opinion in Drug Safety, 7, 587-596. https://doi.org/10.1517/14740338.7.5.587
|
[192]
|
Targum, S. D., Burch, D. J., Asgharnejad, M., Petersen, T., Gomeni, R., & Fava, M. (2014). Use of Band-Pass Filter Analysis to Evaluate Outcomes in an Antidepressant Trial for Treatment Resistant Patients. European Neuropsychopharmacology, 8, 1188-1195. https://doi.org/10.1016/j.euroneuro.2014.06.003
|
[193]
|
Tedeshi, R. E., Tedeshi, D. H., Ames, P. L., Cook, L., Mattis, P. A., & Fellow E. J. (1959). Some Pharmacological Observations on Tranylcypromine (SKF Trans-385), a Potent Inhibitor of Monoamine Oxidase. Proceedings of the Society for Experimental Biolology (New York), 102, 380-381. https://doi.org/10.3181/00379727-102-25256
|
[194]
|
Tetrud, J. W., & Langston, J. W. (1989). The Effect of (-)Deprenyl (Selegiline) on the Natural History of Parkinson’s Disease. Science, 245, 519-522. https://doi.org/10.1126/science.2502843
|
[195]
|
Thiery, J. P. (2002). Epithelial-Mesenchymal Transitions in Tumour Progression. Nature Reviews Cancer, 2, 442-454. https://doi.org/10.1038/nrc822
|
[196]
|
Thomas, S. J., Shin, M., McInnis, M. G., & Bostwick, J. R. (2015). Combination Therapy with Monoamine Oxidase Inhibitors and Other Antidepressants or Stimulants: Strategies for the Management of Treatment-Resistant Depression. Pharmacotherapy, 35, 433-449. https://doi.org/10.1002/phar.1576
|
[197]
|
Tort, S., Urrútia, G., Nishishinya, M. B., & Walitt, B. (2012). Monoamine Oxidase Inhibitors (MAOIs) for Fibromyalgia Syndrome. The Cochrane Database of Systematic Reviews, 4. https://doi.org/10.1002/14651858.CD009807
|
[198]
|
True, L., Coleman, I., Hawley, S., Huang, C. Y., Gifford, D., Coleman, R., Beer, T. M., Gelmann, E., Datta, M., Mostaghel, E., Knudsen, B., Lange, P., Vessella, R., Lin, D., Hood, L., & Nelson, P. S. (2006). A Molecular Correlate to the Gleason Grading system for Prostate Adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 103, 10991-10996. https://doi.org/10.1073/pnas.0603678103
|
[199]
|
Umbarkar, P., Singh, S., Arkat, S., Bodhankar, S. L., Lohidasan, S., & Sitasawad, S. L. (2015). Monoamine Oxidase-A Is an Important Source of Oxidative Stress and Promotes Cardiac Dysfunction, Apoptosis, and Fibrosis in Diabetic Cardiomyopathy. Free Radical Biology & Medicine, 87, 263-273. https://doi.org/10.1016/j.freeradbiomed.2015.06.025
|
[200]
|
Varga, E., & Tringer, L. (1967) Clinical Trial of a New Type of Promptly Acting Psychoenergetic Agent (Phenyl-isopropylmethyl-propinylamine HCl, E-250). Acta Medica Hungarica, 23, 289-295.
|
[201]
|
Versiani, M, Amrein, R., & Montgomery, S. A. (1997). Social Phobia: Long-Term Treatment Outcome and Prediction of Response—A Moclobemide Study. International Clinical Psychopharmacology, 12, 239-254. https://doi.org/10.1097/00004850-199709000-00001
|
[202]
|
Versiani, M., Nardi, A. E., Mundim, F. D., Alves, A. B., Liebowitz, M. R., & Amrein, R. (1992). Pharmacotherapy of Social Phobia. A Controlled Study with Moclobemide and Phenelzine. British Journal of Psychiatry, 161, 353-360. https://doi.org/10.1192/bjp.161.3.353
|
[203]
|
Versiani, M., Nardi, A.E., Mundim, F. D., Pinto, S., Saboya, E., & Kovacs, R. (1996). The Long-Term Treatment of Social Phobia with Moclobemide. International Clinical Psychopharmacology, 11, 83-88. https://doi.org/10.1097/00004850-199606003-00014
|
[204]
|
Versiani, M., Oggeru, U., Alterwain, P., Capponi, R., Dajas, F., Heinze-Martin, G., Marquez, C. A., Poleo, M.A., Rivero-Almanzor, L.E., Rossel, L., Schmid-Burgk, W., & Ucha Udabe, R. (1989). A Double Blind Comparative Trial of Moclobemide vs. Imipramine and Placebo in Major Depressive Episodes. British Journal Psychiatry, 155, 72-77.
|
[205]
|
Villarinho, J. G., de Vargas Pinheiro, K., de Vargas Pinheiro, F., Oliveira, S. M., Machado, P., Martins, M. A., Bonacorso, H. G., Zanatta, N., Fachinetto, R., & Ferreira, J. (2013). The Antinociceptive Effect of Reversible Monoamine Oxidase-A Inhibitors in a Mouse Neuropathic Pain Model. Progress in Neuro-Psychopharmacology & Biochemical Psychiatry, 44, 136-142. https://doi.org/10.1016/j.pnpbp.2013.02.005
|
[206]
|
Villarinho, J. G., Oliveira, S. M., Silva, C. R, Cabreira, T. N., & Ferreira, J. (2012). Involvement of Monoamine Oxidase B on Models of Postoperative and Neuropathic Pain in Mice. European Journal of Pharmacology, 690, 107-114. https://doi.org/10.1016/j.ejphar.2012.06.042
|
[207]
|
Visfeldt, J. (1961) [Iproniazid Poisoning. A Fatal Case with Liver and Kidney Damage]. Ugeskrift for Læger, 123, 1727-1728.
|
[208]
|
Vogt, M. (1969). Release from Brain Tissue of Compounds with Possible Transmitter Function: Interaction of Drugs with These Substances. British Journal Pharmacology, 37, 325-337. https://doi.org/10.1111/j.1476-5381.1969.tb10570.x
|
[209]
|
Von Knorring, L., & Oreland, L. (1985) Personality Traits and Platelet Monoamine Oxidase in Tobacco Smokers. Psychological Medicine, 15, 327-334. https://doi.org/10.1017/S0033291700023606
|
[210]
|
Weinberger, A. H., Reutenauer, E. L., Jatlow, P. I., O’Malley, S. S., Potenza, M. N., & George, T.P . (2010). A Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Oral Selegiline Hydrochloride for Smoking Cessation in Nicotine-Dependent Cigarette Smokers. Drug and Alcohol Dependence, 107, 188-195. https://doi.org/10.1016/j.drugalcdep.2009.10.009
|
[211]
|
Wimbiscus, M., Kostenko, O., & Malone D. (2010). MAO Inhibitors: Risks, Benefits, and Lore. Cleve Clinic Journal of Medicine, 77, 859-882. https://doi.org/10.3949/ccjm.77a.09103
|
[212]
|
Wise, R. A., & Rompre, P. P. (1989). Brain Dopamine and Reward. Annual Review of Psychology, 40, 191-225. https://doi.org/10.1146/annurev.ps.40.020189.001203
|
[213]
|
Wouters, J. (1998). Structural Aspects of Monoamine Oxidase and Its Reversible Inhibition. Current Medicinal Chemistry, 5, 137-162.
|
[214]
|
Wu, J. B., Lin, T. P., Gallagher, J. D., Kushal, S., Chung, L. W., Zhau, H. E., Olenyuk, B. Z., & Shih, J. C. (2015) Monoamine Oxidase A Inhibitor-Near-Infrared Dye Conjugate Reduces Prostate Tumor Growth. Journal of the American Chemical Society, 137, 2366-2374. https://doi.org/10.1021/ja512613j
|
[215]
|
Wu, J. B., Shao, C., Li, X., Li, Q., Hu, P., Shi, C., Li, Y., Chen, Y. T., Yin, F., Liao, C. P., Stiles, B. L., Zhau, H. E., Shih, J. C., & Chung, L. W. (2014). Monoamine Oxidase A Mediates Prostate Tumorigenesis and Cancermetastasis. Journal of Clinical Investigation, 124, 2891-2908. https://doi.org/10.1172/JCI70982
|
[216]
|
Wu, M. Y., Esteban, G., Brogi, S., Shionoya, M., Wang, L., Campiani, G., Unzeta, M., Inokuchi, T., Butini, S., & Marco-Contelles, J. (2016). Donepezil-Like Multifunctional Agents: Design, Synthesis, Molecular Modeling and Biological Evaluation. European Journal of Medicinal Chemistry, 121, 864-879.
|
[217]
|
Wyatt, R. J., Potkin, S. G., Bridge, T. P., Phelps, B. H., & Wise, C. D. (1980). Monoamine Oxidase in Schizophrenia: An Overview. Schizophrenia Bulletin, 6, 199-207. https://doi.org/10.1093/schbul/6.2.199
|
[218]
|
Xu, S., Adisetiyo, H., Tamura, S., Grande, F., Garofalo, A., Roy-Burman, P., & Neamati, N. (2015). Dual Inhibition of Survivin and MAOA Synergistically Impairs Growth of PTEN-Negative Prostate Cancer. British Journal of Cancer, 113, 242-251. https://doi.org/10.1038/bjc.2015.228
|
[219]
|
Yáñez, M., & Viña, D. (2013). Dual Inhibitors of Monoamine Oxidase and Cholinesterase for the Treatment of Alzheimer Disease. Current Topic in Medicinal Chemistry, 13, 1692-1706. https://doi.org/10.2174/15680266113139990120
|
[220]
|
Youdim, M. B. (1975). Monoamine Oxidase. Its Inhibition. Modern Problems of Psychopsychiatry, 10, 65-88. https://doi.org/10.1159/000397920
|
[221]
|
Zarate Jr., C. A., Tohen, M., Baraibar, G., Kando, J. C., & Mirin, J. (1995). Prescribing trends of Antidepressants in Bipolar Depression. Journal of Clinical Psychiatry, 56, 260-264.
|
[222]
|
Zeller, E. A., Barsky, J., Fouts, J. R., Kirchheimer, W. F., & Van Orden, L. S. (1952). Influence of Isonicotinic Acid (INH) and 1-Isonicotinic-2-Isopropyl-Hydrazide (IIH) on Bacterial and Mammalian Enzymes. Experimentia, 8, 349-350. https://doi.org/10.1007/BF02174413
|
[223]
|
Zellner, M., Baurederm M., Rappoldm E., Bugert, P., Kotzailias, N., Babeluk, R., Baumgartner, R., Attems, J., Gerner, C., Jellinger, K., Roth, E., Oehler, R., & Umlauf, E. (2012). Comparative Platelet Proteome Analysis Reveals an Increase of Monoamine Oxidase-B Protein Expression in Alzheimer’s Disease but Not in Non-Demented Parkinson’s Disease Patients. Journal of Proteomics, 75, 2080-2092. https://doi.org/10.1016/j.jprot.2012.01.014
|
[224]
|
Zhao, H., Flamand, V., & Peehl, D. M. (2009). Anti-Oncogenic and Pro-Differentiation Effects of Clorgyline, a Monoamine Oxidase A Inhibitor, on High Grade Prostate Cancer Cells. BMC Medical Genomics, 2, 55-69. https://doi.org/10.1186/1755-8794-2-55
|
[225]
|
Zheng, H., Fridkin, M., & Youdim, M. B. (2012). From Antioxidant Chelators to Site-Activated Multi-Target Chelators Targeting Hypoxia Inducing Factor, Beta-Amyloid, Acetylcholinesterase and Monoamine Oxidase A/B. Mini-Reviews in Medicinal Chemistry, 12, 364-370. https://doi.org/10.2174/138955712800493898
|